Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00340834
Status:
COMPLETED
Last Update Posted:
2017-09-21
First Post:
2006-06-19
Brief Title:
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-month Double-blind Randomized Multicenter Active-controlled Parallel-group Study Comparing the Efficacy and Safety of 05 mg and 125 mg Fingolimod FTY720 Administered Orally Once Daily Versus Interferon ß-1a Avonex Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRANSFORMS
Brief Summary:
This study assessed the safety tolerability and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CFTY720D2302E1 | OTHER | Novartis | None |